-
1.发明公开公开(公告)号：US20240360457A1
公开(公告)日：2024-10-31
申请号：US18765587
申请日：2024-07-08
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the cancer cell via endocytosis.
-
2.发明公开公开(公告)号：US20240150771A1
公开(公告)日：2024-05-09
申请号：US18407815
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
-
公开(公告)号：US11246939B2
公开(公告)日：2022-02-15
申请号：US16573351
申请日：2019-09-17
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Sun Hwa Kim , Ick Chan Kwon , In-San Kim , Kwangmeyung Kim , Yoosoo Yang , Young-Ji Ko
IPC: A61K47/55 , A61K47/54 , A61K31/713 , C12N15/113 , C07K14/705 , A61P35/00 , A61K38/00
Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.
-
公开(公告)号：US12006502B2
公开(公告)日：2024-06-11
申请号：US18407815
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00 , C12Q1/68
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
-
5.发明公开公开(公告)号：US20240191237A1
公开(公告)日：2024-06-13
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240043846A1
公开(公告)日：2024-02-08
申请号：US18057050
申请日：2022-11-18
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.
-
7.发明授权Gelatin-based nanoparticle complex for tumor-targeted delivery of siRNA and method for preparing the same 有权用于肿瘤靶向递送siRNA的明胶基纳米颗粒复合物及其制备方法公开(公告)号：US09415060B2
公开(公告)日：2016-08-16
申请号：US14340845
申请日：2014-07-25
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwang Meyung Kim , Sun Hwa Kim , Ick Chan Kwon , Ji Young Yhee , Sojin Lee
IPC: A61K47/48 , A61K31/7088 , A61K31/713
CPC classification number: A61K31/7088 , A61K31/713 , A61K47/6435 , A61K47/6903 , A61K47/6929
Abstract: Disclosed is a gelatin-based nanoparticle complex for tumor-targeted delivery of siRNA for specific gene silencing in tumor cells. The gelatin-based nanoparticle complex includes: poly-siRNA chains whose ends are modified with thiol groups; and thiolated gelatin bound to the poly-siRNA chains through disulfide crosslinking and charge interactions. The gelatin-based nanoparticle complex is not degraded in the bloodstream and can be efficiently absorbed into tumor cells without cytotoxicity. The delivered siRNA can effectively silence target gene expression. Also disclosed is a method for preparing the gelatin-based nanoparticle complex.
Abstract translation: 公开了一种用于肿瘤靶向递送siRNA用于肿瘤细胞中特异性基因沉默的明胶基纳米颗粒复合物。 基于明胶的纳米颗粒复合物包括：末端用巯基修饰的多siRNA链; 并通过二硫键交联和电荷相互作用将与siRNA结合的多聚siRNA链结合在一起。 基于明胶的纳米颗粒复合物在血液中不降解，并且可以有效地吸收到肿瘤细胞中而没有细胞毒性。 递送的siRNA可以有效地沉默靶基因表达。 还公开了一种制备明胶基纳米颗粒复合物的方法。
-
8.发明公开公开(公告)号：US20240325550A1
公开(公告)日：2024-10-03
申请号：US18618258
申请日：2024-03-27
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: A61K47/64 , A61P35/00 , C12N15/113
CPC classification number: A61K47/64 , A61P35/00 , C12N15/113 , C12N2310/14 , C12N2310/141
Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.
-
公开(公告)号：US20190307794A1
公开(公告)日：2019-10-10
申请号：US16379523
申请日：2019-04-09
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Yeon-Sun HONG , Hyo Suk Kim , Yoo Soo Yang , Sun Hwa Kim , In-San Kim , Ick Chan Kwon
IPC: A61K35/15 , C12N5/0786 , C12N5/0784 , C12N5/0775 , A61K9/127 , C12N5/00
Abstract: The present invention relates to a method of inducing trans-differentiating a first type of immune cell into a second type of immune cell comprising: isolating exosomes from the second type of immune cell that has undergone differentiation, and treating the first type of immune cell or a cell population including the first type of immune cell with the isolated exosomes in vitro.
-
公开(公告)号：US12139713B2
公开(公告)日：2024-11-12
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00 , C12Q1/68
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.019 seconds)
